BridgeMD
Effect of briquilimab in patients with patches of itching skin because of chronic spontaneous urticaria (CSU) despite treatment with antihistamines
EU CTIS ID: 2023-505446-25-00
What this study is testing
Evaluate the safety and tolerability of briquilimab
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Written informed consent after the nature of the trial has been fully explained and before performing any trial related assessments
- Males and females 18 years old and above
- i. For Cohorts 1, 2, 3, 4a, 4b, 5, 5b, 6 and 7:Diagnosis of symptomatic CSU despite treatment as defined by: a) Diagnosis of CSU for ≥ 6 months; b) The presence of itch and hives for ≥ 8 consecutive weeks at any time prior to Screening despite current use of H1-antihistamines (as reported by the participant); c) The presence of itch and hives for ≥ 8 consecutive weeks at any time prior to Screening despite treatment with omalizumab or intolerance to omalizumab (as reported by the participant); d) UAS7 of ≥ 16 and ISS7 of ≥ 8 on Days –10 through Day –3 of Screening (not more than 2 missing entries during that period, re-screening may be considered with Medical Monitor approval)ii. For Cohorts 8 and 9: Diagnosis of symptomatic CSU despite treatment as defined by: a. Diagnosis of CSU for ≥ 6 months (as per local and international guidance)b. The presence of itch and hives for ≥ 8 consecutive weeks at any time prior to Screening despite current use of H1-antihistamines (as reported by the participant) c. Participants may be omalizumab naïve or have been previously exposed to omalizumab independent of treatment duration or response, and require an 8-week washout period prior to the first dose of IP. The 8-week washout is not required for participants who are refractory to omalizumab. Note: Omalizumab-refractory participants are defined as those treated with standard doses of omalizumab (i.e., 300 mg omalizumab every 4 weeks) for at least 3 consecutive months and who had no improvement in CSU, and remained symptomatic resulting in omalizumab discontinuation, as confirmed by investigator assessment. d. UAS7 of ≥ 16 and ISS7 of ≥ 8 on 7 consecutive days between Day -10 through Day -1 of Screening (not more than 2 missing entries during that period, re-screening may be considered with Medical Monitor approval)
- Use of H1-antihistamines on stable dose up to four-fold of the approved dose since Screening and not expected to change during first 12 weeks of the trial
- Blood counts at Screening with: a) Hemoglobin: ≥ 11 g/dl; b) Platelets: ≥ 100,000/mm3; c) Leucocytes: ≥ 3,000/mm3; d) Neutrophils: ≥ 2,000/mm3
- Willing and able to complete a daily diary for the duration of the trial and adhere to the trial visit schedule
You likely can't join if
- Women who are pregnant or nursing or intend to become pregnant during the course of the trial
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5 x Upper limit of normal (ULN) at Screening
- Serum total bilirubin >1.5 x ULN, unless attributable to Gilbert’s syndrome
- Estimated creatinine clearance (eCrCl) by Cockcroft-Gault equation using total body weight < 60 mL/min
- Known HIV+, active hepatitis B or hepatitis C infection, or acute/long-COVID
- Major abdominal or thoracic surgery within 8 weeks prior to Screening or planned surgery during trial participation
See the full eligibility criteria
Who can join
- Written informed consent after the nature of the trial has been fully explained and before performing any trial related assessments
- Males and females 18 years old and above
- i. For Cohorts 1, 2, 3, 4a, 4b, 5, 5b, 6 and 7:Diagnosis of symptomatic CSU despite treatment as defined by: a) Diagnosis of CSU for ≥ 6 months; b) The presence of itch and hives for ≥ 8 consecutive weeks at any time prior to Screening despite current use of H1-antihistamines (as reported by the participant); c) The presence of itch and hives for ≥ 8 consecutive weeks at any time prior to Screening despite treatment with omalizumab or intolerance to omalizumab (as reported by the participant); d) UAS7 of ≥ 16 and ISS7 of ≥ 8 on Days –10 through Day –3 of Screening (not more than 2 missing entries during that period, re-screening may be considered with Medical Monitor approval)ii. For Cohorts 8 and 9: Diagnosis of symptomatic CSU despite treatment as defined by: a. Diagnosis of CSU for ≥ 6 months (as per local and international guidance)b. The presence of itch and hives for ≥ 8 consecutive weeks at any time prior to Screening despite current use of H1-antihistamines (as reported by the participant) c. Participants may be omalizumab naïve or have been previously exposed to omalizumab independent of treatment duration or response, and require an 8-week washout period prior to the first dose of IP. The 8-week washout is not required for participants who are refractory to omalizumab. Note: Omalizumab-refractory participants are defined as those treated with standard doses of omalizumab (i.e., 300 mg omalizumab every 4 weeks) for at least 3 consecutive months and who had no improvement in CSU, and remained symptomatic resulting in omalizumab discontinuation, as confirmed by investigator assessment. d. UAS7 of ≥ 16 and ISS7 of ≥ 8 on 7 consecutive days between Day -10 through Day -1 of Screening (not more than 2 missing entries during that period, re-screening may be considered with Medical Monitor approval)
- Use of H1-antihistamines on stable dose up to four-fold of the approved dose since Screening and not expected to change during first 12 weeks of the trial
- Blood counts at Screening with: a) Hemoglobin: ≥ 11 g/dl; b) Platelets: ≥ 100,000/mm3; c) Leucocytes: ≥ 3,000/mm3; d) Neutrophils: ≥ 2,000/mm3
- Willing and able to complete a daily diary for the duration of the trial and adhere to the trial visit schedule
What rules you out
- Women who are pregnant or nursing or intend to become pregnant during the course of the trial
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5 x Upper limit of normal (ULN) at Screening
- Serum total bilirubin >1.5 x ULN, unless attributable to Gilbert’s syndrome
- Estimated creatinine clearance (eCrCl) by Cockcroft-Gault equation using total body weight < 60 mL/min
- Known HIV+, active hepatitis B or hepatitis C infection, or acute/long-COVID
- Major abdominal or thoracic surgery within 8 weeks prior to Screening or planned surgery during trial participation
- Male participants (who are not vasectomized) who are not willing to use highly effective contraceptive methods (when having sexual intercourse with a female partner of childbearing potential) and who are not willing to abstain from sperm donation during the trial and for at least 150 days after last IP dosing. A male participant is considered vasectomized if he had a vasectomy at least 4 months prior to Screening and if he has received post-surgical medical assessment of the surgical success of the vasectomy
- Female participants of childbearing potential not willing to use highly effective contraceptive methods during the trial and for at least 150 days after last IP dosing. Women of non-childbearing potential, must be surgically sterile (i.e., had undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or be in menopausal state (at least 1 year without menses).
- Participation in another research trial involving the use of an IP within the last 30 days (or 5 half-lives of IP, whichever is longer) prior to Screening
- Any known contraindications or hypersensitivity to any component of the IP, drugs of similar chemical classes (i.e., to murine, chimeric or human antibodies) or antihistamines or leukotrienes
- Any other acute or chronic medical or psychiatric condition or laboratory abnormality that could increase the risk associated with trial participation or IP administration or could interfere with the interpretation of trial results and, in the judgment of the Investigator, would make the participant inappropriate for entry into the trial
- Dominant comorbid chronic urticaria with a clearly defined predominant or sole trigger (chronic inducible urticaria) including urticaria factitia (symptomatic dermographism), cold-, heat-, solar-, pressure-, delayed pressure-, aquagenic-, cholinergic-, or contact urticaria
- Participants not willing to abstain from blood donations while being on the trial (until EOT Visit)
- Close affiliation with the Investigator (e.g., a close relative, financially dependent on the trial site) or participant who is an employee of the Sponsor’s company
- Other active diseases with possible symptoms of urticaria, wheals or angioedema, including urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa), and hereditary or acquired angioedema (e.g., due to C1 inhibitor deficiency)
- Any other active skin disease associated with chronic itching that might confound the trial evaluations and results, in the opinion of the Investigator (e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, etc.)
- History of anaphylaxis
- Any H2 antihistamine, leukotriene receptor antagonist or tricyclic antidepressant use within 3 days prior to Screening
- Experimental monoclonal antibody therapy (e.g., dupilumab, ligelizumab, etc.) within 6 months or Janus kinase (JAK) inhibitors within 5 half-lives prior to first IP dosing
- Immunosuppressive therapy (e.g., systemic corticosteroids, cyclosporine, methotrexate, dapsone, cyclophosphamide, tacrolimus and mycophenolate mofetil, hydroxychloroquine, etc.) within 4 weeks (or 5 half-lives, whichever is longer) prior to first IP dosing
- Electrocardiogram (ECG) findings at Screening that are considered clinically significant
The study team makes the final eligibility decision.
Where it's taking place
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.